ClinicalTrials.gg
RecruitingNCT07148232Updated Nov 21, 2025

Extended Intervention for Tobacco Use (EXIT) for People Experiencing Homelessness

A Phase 4 interventional study of Nicotine Replacement Therapy (NRT) and Wellness Coaching in Tobacco Cessation, Tobacco Abstinence and Tobacco Use, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Tobacco Use Cessation by University of California, San Francisco — 2 open to participants now, 2 under way, none of them phase 3. Tobacco Use Cessation · University of California, San Francisco.

Planned enrollment
7th of 11
150 · median 165
Started
2025
with 1 other
Phase 4
2 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Tobacco Use Cessation by University of California, San Francisco, this one is the 7th largest by planned enrollment, is one of 2 that started in 2025, is one of 2 in phase 4, and was the 11th registered.

Tobacco Use Cessation

276 studies on the registry are indexed under Tobacco Use Cessation; 45 are open to participants now.

Browse Tobacco Use Cessation studies →

Open to participants now

2 of the 11 studies in Tobacco Use Cessation by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 23 Tobacco Use Cessation studies recruiting now, 16 (70%) set no upper age limit and 6 (26%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Tobacco Use Cessation by University of California, San Francisco, or all of them as a file.
02

Study summary

This study is investigating tobacco use and providing tobacco treatment among people experiencing homelessness in California, in San Francisco and Los Angeles.

Read the detailed description

PRIMARY OBJECTIVES:

I. Biochemically verified 7-day point prevalence tobacco abstinence at 6-months follow-up.

II. Use expired carbon monoxide (CO) to confirm self-reports of abstinence using a cut-off of CO ≤5 parts per million (ppm).

SECONDARY OBJECTIVES:

I. Biochemically-verified 7-day point prevalence tobacco abstinence at 3-months follow-up.

II. Measured at 6-months follow-up, a total number of expired carbon monoxide (CO-negative samples).

III. Measured at 6-months follow-up, longest duration of abstinence (i.e., total number of uninterrupted days abstinent), proportion with 50% reduction in expired CO for those who do not quit smoking.

IV. Use expired CO to confirm self-reports of abstinence using a cut-off of CO ≤5 ppm.

OUTLINE:

Participants will be randomized to one of two groups:

  • Intervention group receives 6 months of pharmacist consultation, monthly delivery of nicotine replacement therapy, and telephone wellness coaching.
  • Control group receives pharmacist consultation and monthly delivery of nicotine replacement therapy for 3 months.

Participants will be followed up at 1, 3 and 6 months.

03

Conditions studied

  • Tobacco Cessation
  • Tobacco Abstinence
  • Tobacco Use
  • Tobacco Use Cessation
  • Tobacco Dependence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older
  2. Able to understand study procedures and to comply with them for the entire length of the study.
  3. Ability of individual to understand a written document, and the willingness to sign it.
  4. Staying at the recruitment site and meeting criteria for homelessness as defined by the Homeless Emergency and Rapid Transition to Housing Act.
  5. Current smoking (smoking at least 5 cigarettes per day (cpd), verified via expired carbon monoxide (CO) >= 8 ppm using Micro+pro Smokerlyzer).
  6. Having an intention to quit smoking within the next six months.
  7. English speaking.

Exclusion criteria

Exclusion Criteria:

  1. to any study-related procedure or assessment.
  2. Reasons that preclude the use of nicotine replacement therapy (NRT) (e.g., pregnancy or myocardial infarction in the past two weeks).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Treatment (extended intervention for tobacco use)

    Participants receive pharmacist provided one-time tobacco treatment using the five As: Ask, Advise, Assess, Assist and Arrange (5As) model and receives an initial monthly delivery of nicotine replacement therapy (NRT) for 3 months. Participants then receive the extended intervention for tobacco use (EXIT) that consists of: 1) health coach-delivered, weekly-to-monthly wellness-focused telephone coaching for 6 months addressing tobacco use within the context of co-occurring psychiatric and substance-use comorbidities and other life stressors, and 2) an additional session of pharmacist-delivered 5As with monthly delivery of NRT for an additional 6 months. Participants will provide CO samples for biochemical verification of smoking abstinence and complete questionnaires throughout the study.

    Drug: Nicotine Replacement Therapy (NRT) · Behavioral: Wellness Coaching

  • Other
    Pharm-only

    Participants receive pharmacist provided one-time tobacco treatment using the 5As and receive monthly delivery of NRT for 3 months. Participants will provide CO samples for biochemical verification of smoking abstinence and complete questionnaires throughout the study.

    Drug: Nicotine Replacement Therapy (NRT)

Interventions

  • DrugNicotine Replacement Therapy (NRT)

    NRT will be administered as patch (transdermal), gum, or lozenge

    Also known as: NRT

  • BehavioralWellness Coaching

    Delivered via phone call

06

What researchers measure

Primary outcomes

  1. Percentage of participants who attended coaching sessions

    The percentage of participants who attended at least 75% or 7 of the 14 coaching sessions will be reported.

    Time frame: up to 6 months

  2. Percentage of participants who used nicotine replacement therapy (NRT)

    The percentage of participants who used at least 75% will adhere to using NRT for at least half of the treatment duration will be reported.

    Time frame: up to 6 months

  3. 7-day point prevalence tobacco abstinence at month 6

    Biochemically verified 7-day point prevalence tobacco abstinence at 6-months follow-up will be reported.

    Time frame: 6 months

Secondary outcomes

  1. 7-day point prevalence tobacco abstinence at month 3

    Biochemically verified 7-day point prevalence tobacco abstinence at 3-months follow-up will be reported.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jun 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Aug 29, 2025
StartActual
Nov 14, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07148232
Collaborators
Tobacco Related Disease Research Program
Responsible party
Sponsor
First posted
Aug 29, 2025
Start date
Nov 14, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 21, 2025

Study contacts

Jessica Alway
Contact
jessica.alway@ucsf.edu
877-827-3222
Maya Vijayaraghavan, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion